[
    {
        "outcome_uid": "38c014e9",
        "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target",
        "intervention": "Switch to a 3rd TNF Inhibitor",
        "comparator": "Switch to Rituximab",
        "outcome": "Disease activity (follow up: 6 months; assessed with DAS 28-ESR (Lower values \u2013 > benefit) (MCID -1.17)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "5f4ff353"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Observational Study",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switching to a 3rd TNF Inhibitor": "43",
                    "switching to rituximab": "58"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.35 lower (1.82 lower to 1.12 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "67c7b09b",
        "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target",
        "intervention": "Switch to a 3rd TNF Inhibitor",
        "comparator": "Switch to Rituximab",
        "outcome": "Low disease activity (follow up: 6 months; assessed with DAS28 \u2264 3.2)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "5f4ff353"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Observational Study",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switching to a 3rd TNF Inhibitor": "6/35 (17.1%)",
                    "switching to rituximab": "20/69 (29.0%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.59 (0.26 to 1.34)",
                    "Absolute Effect (95% CI)": "119 fewer per 1,000 (from 214 fewer to 99 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "d082600d",
        "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target",
        "intervention": "Switch to a 3rd TNF Inhibitor",
        "comparator": "Switch to Rituximab",
        "outcome": "Disability (follow up: 1 year; assessed with HAQ-DI (Lower values \u2013 > benefit) (MCID -0.22 )",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "5f4ff353"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Observational Study",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switching to a 3rd TNF Inhibitor": "35",
                    "switching to rituximab": "54"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0 (0.53 lower to 0.53 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "bb7ff9b9",
        "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target",
        "intervention": "Switch to a 3rd TNF Inhibitor",
        "comparator": "Switch to Rituximab",
        "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "5f4ff353"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Observational Study",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switching to a 3rd TNF Inhibitor": "15/64 (23.4%)",
                    "switching to rituximab": "10/90 (11.1%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.11 (1.01 to 4.39)",
                    "Absolute Effect (95% CI)": "123 more per 1,000 (from 1 more to 377 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "ef1f4075",
        "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target",
        "intervention": "Switch to a 3rd TNF Inhibitor",
        "comparator": "Switch to Rituximab",
        "outcome": "Withdrawal due to adverse events (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "5f4ff353"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Observational Study",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switching to a 3rd TNF Inhibitor": "14/64 (21.9%)",
                    "switching to rituximab": "1/90 (1.1%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 19.69 (2.66 to 145.95)",
                    "Absolute Effect (95% CI)": "208 more per 1,000 (from 18 more to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]